Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$15.65 USD
+0.93 (6.32%)
Updated May 9, 2024 04:00 PM ET
After-Market: $15.67 +0.02 (0.13%) 6:06 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
Income Statements
Fiscal Year end for Catalyst Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 398 | 214 | 141 | 119 | 102 |
Cost Of Goods | 52 | 34 | 22 | 17 | 15 |
Gross Profit | 346 | 180 | 119 | 102 | 88 |
Selling & Adminstrative & Depr. & Amort Expenses | 259 | 78 | 67 | 61 | 56 |
Income After Depreciation & Amortization | 87 | 102 | 52 | 41 | 32 |
Non-Operating Income | 8 | 3 | 0 | 1 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | 95 | 105 | 53 | 42 | 33 |
Income Taxes | 23 | 22 | 13 | -33 | 2 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 71 | 83 | 39 | 75 | 32 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 71 | 83 | 39 | 75 | 32 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 120 | 103 | 53 | 42 | 32 |
Depreciation & Amortization (Cash Flow) | 33 | 1 | 0 | 1 | 0 |
Income After Depreciation & Amortization | 87 | 102 | 52 | 41 | 32 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 113.75 | 111.38 | 107.80 | 106.24 | 106.02 |
Diluted EPS Before Non-Recurring Items | 1.83 | 0.75 | 0.37 | 0.40 | 0.30 |
Diluted Net EPS (GAAP) | 0.63 | 0.75 | 0.37 | 0.71 | 0.30 |
Fiscal Year end for Catalyst Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 110.57 | 102.69 | 99.58 | 85.37 |
Cost Of Goods | NA | 15.81 | 14.17 | 12.05 | 9.95 |
Gross Profit | NA | 94.76 | 88.52 | 87.54 | 75.42 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 53.07 | 125.71 | 40.84 | 39.81 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 41.69 | -37.19 | 46.70 | 35.61 |
Non-Operating Income | NA | 5.02 | -0.83 | 1.81 | 1.70 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | 46.71 | -38.02 | 48.51 | 37.31 |
Income Taxes | NA | 11.86 | -7.26 | 10.75 | 7.75 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 34.84 | -30.76 | 37.76 | 29.57 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 34.84 | -30.76 | 37.76 | 29.57 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 113.76 | 106.57 | 113.67 | 113.99 |
Diluted EPS Before Non-Recurring Items | NA | 0.49 | -0.26 | 0.33 | 0.26 |
Diluted Net EPS (GAAP) | NA | 0.33 | -0.29 | 0.33 | 0.26 |